Allurion Technologies Inc. (ALUR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 38 | 64 | 53 | 32 | 15 | 13 | 14 |
| Operating profit | $m | -30 | -27 | ||||||
| Net profit | $m | -0 | -12 | -38 | -81 | -26 | -29 | -33 | - |
| EPS reported | $ | -57.15 | -56.40 | ||||||
| Operating cashflow per share | $ | -57.55 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -57.55 | - | ||||||
| Free cash flow | $m | -29 | -23 | ||||||
| Net debt | $m | 24 | 23 | ||||||
| Book value equity | $m | -77 | -78 | ||||||
| Book value per share | $ | -153.5 | -87.54 | ||||||
| Number of shares | m | 0.5 | 0.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.12 | -0.12 | ||||||
| P/S LTM | x | 0.61 | 0.74 | ||||||
| P/FCF LTM | x | -0.32 | -0.41 | ||||||
| EV/EBITDA LTM | x | -1.19 | -0.83 | ||||||
| EV/Sales LTM | x | 2.16 | - | ||||||
| Earnings Yield LTM | % | -3.10% | - | ||||||
| FCF Yield | % | -311.93% | -244.60% | ||||||
| Quality | |||||||||
| ROE | % | +37.25% | - | ||||||
| ROIC | % | -5.20% | - | ||||||
| Operating margin | % | -1.98% | - | ||||||
| Gross margin | % | +62.84% | - | ||||||
| FCF/Sales | % | -190.06% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -52.57% | -60.77% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.00 | -0.77 | ||||||
| Net Debt/EBITDA | x | -0.85 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | +3.13% | - | ||||||
| Net debt/Equity | x | -0.31 | -0.30 | ||||||
| Gross debt/equity | x | -0.38 | -0.38 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurion Balloon – a novel, non-surgical, swallowable intragastric device engineered to promote significant weight loss. This program is further enhanced by the Allurion Virtual Care Suite, which provides sophisticated AI-powered remote patient monitoring, a specialized behavior modification curriculum, encrypted messaging capabilities, and virtual telehealth consultations. The firm's main operational base is located in Natick, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurion Balloon – a novel, non-surgical, swallowable intragastric device engineered to promote significant weight loss. This program is further enhanced by the Allurion Virtual Care Suite, which provides sophisticated AI-powered remote patient monitoring, a specialized behavior modification curriculum, encrypted messaging capabilities, and virtual telehealth consultations. The firm's main operational base is located in Natick, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free